What is Mosquirix™?
Mosquirix™, also known as RTS,S, is an injectable malaria vaccine developed by GSK. GSK led the development of RTS,S over a 30-year period. In 2001, GSK began a collaboration with the PATH Malaria Vaccine Initiative (MVI) to continue developing RTS,S. An advanced clinical trials (referred to below as Phase 3 trials) to assess the vaccine’s efficacy and safety was conducted between 2009 and 2014 through a partnership that involved GSK, MVI (with support from the Bill & Melinda Gates Foundation) and a network of African research centres at 11 sites in 7 countries including Ghana.
How does Mosquirix ™ act?
MosquirixTM acts against Plasmodium falciparum, the most deadly malaria parasite globally, and the most prevalent in Ghana and the rest of sub-Saharan Africa. MosquirixTM offers no protection against Plasmodium vivax malaria, a strain of the malaria parasite which predominates in many countries outside of Africa.
Why do we need a malaria vaccine?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What makes MosquirixTM different from other malaria candidate vaccines currently under development?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
Why is Ghana to take part in the malaria vaccine implementation programme?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What role could MosquirixTM potentially play in Ghana’s malaria control programme?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What is the purpose of the World Health Organization (WHO) Malaria Vaccine Pilot Implementation Programme?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What were the criteria for the selection of countries to participate in the Malaria Vaccine Implementation Programme?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What is malaria?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
In which countries was the Phase 3 trial conducted?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What role did Ghanaian researchers play in the development of MosquirixTM?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What were the results from the Phase 3 trial?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
Side effects
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
When will the Malaria Vaccine Implementation Programme be launched?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
Who will fund the Malaria Vaccine Implementation Programme?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What is the policy for the registration/licensure of MosquirixTM?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
Where will the Pilot Implementation Programme take place in Ghana?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What goes into the Selection of the Regions for the Pilot Implementation Programme?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
Will the Vaccine be supplied free of charge to Ghanaians?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
How will the vaccine be given?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
What is the position of the WHO on the malaria vaccine?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
Malaria Control Measures
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
Will Vaccination with the RTS,S malaria vaccine be optional or compulsory?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
Why is the RTS,S malaria vaccine not for adults?
Historically, vaccines have proved to be among the most effective means of preventing disease and saving lives, particularly in the case of infectious diseases. While malaria death rates in sub-Saharan Africa have dropped in recent years with the scale-up of existing malaria control measures, the disease continues to take a heavy toll: there were 212 million malaria cases worldwide in 2015 with 429,000 deaths. The majority of deaths are in children under the age of five, living in sub-Saharan Africa. In Ghana, malaria caused 2,133 deaths in 2015, approximately 51% of which afflict children under the age of five.
